Mestag Therapeutics strengthens top team at the double

CEO Susan Hill said: “As we approach our first clinical trial initiation, Jan’s experience across all stages of preclinical and early clinical development, together with Alison’s global leadership experience and extensive legal expertise, will further empower team Mestag to progress our impactful new antibody therapies to patients as efficiently as possible.”

Dr Endell brings over 15 years of expertise in drug development and strategic leadership with a successful track record in advancing drugs from early stages to clinical development and commercialisation.

Throughout his career, he has held key positions in private and public biotech companies, with a particular expertise in cancer and autoimmune disease drug development.

Before joining Mestag, Dr Endell served as Chief Scientific Officer at Veraxa Biotech, where he led its transformation into a development company.

Alison Hood is an experienced general counsel in the biotech and pharma sector. She was previously VP & Head of Legal, International at Aimmune Therapeutics, a position she retained following its acquisition by Nestlé Health Science in 2020.

With responsibility for all legal activities outside the US and a member of the executive team, Hood led the legal function supporting the clinical, regulatory and commercial teams through approval and launch of Palforzia® across Europe, and the expansion of the business from its original UK base to include offices in Ireland, Germany, France and Switzerland.

Before that she was General Counsel at Vernalis plc, and Associate General Counsel at Celltech plc.

Mestag harnesses new insights into fibroblast immunology to develop impactful treatments for patients with cancer and inflammatory diseases. It is progressing a pipeline of sophisticated first-in-class antibodies designed to direct and drive the immune system using known and emerging fibroblast-immune biology for a distinctly differentiated class of therapeutics.